Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T01:35:18.923Z Has data issue: false hasContentIssue false

Prevalence of and Risk Factors for Vancomycin-Resistant Staphylococcus aureus Precursor Organisms in Southeastern Michigan

Published online by Cambridge University Press:  10 May 2016

Valerie S. Albrecht
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
Marcus J. Zervos
Affiliation:
Division of Infectious Diseases, Henry Ford Health System, Detroit, Michigan
Keith S. Kaye
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Detroit, Michigan
Pritish K. Tosh
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia; and Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
Samia Arshad
Affiliation:
Division of Infectious Diseases, Henry Ford Health System, Detroit, Michigan
Kayoko Hayakawa
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Detroit, Michigan
Alexander J. Kallen
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
Linda K. McDougal
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
Brandi M. Limbago
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
Alice Y. Guh*
Affiliation:
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
*
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329 ([email protected]).

Abstract

We assessed for vancomycin-resistant Staphylococcus aureus (VRSA) precursor organisms in southeastern Michigan, an area known to have VRSA. The prevalence was 2.5% (pSK41-positive methicillin-resistant S. aureus, 2009–2011) and 1.5% (Inc18-positive vancomycin-resistant Enterococcus, 2006–2013); Inc18 prevalence significantly decreased after 2009 (3.7% to 0.82%). Risk factors for pSK41 included intravenous vancomycin exposure.

Infect Control Hosp Epidemiol 2014;35(12):1531–1534

Type
Brief Report
Copyright
© 2014 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Limbago, BM, Kallen, AJ, Zhu, W, Eggers, P, McDougal, LK, Albrecht, VS. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol 2014;52:9981002.Google Scholar
2. Centers for Disease Control and Prevention (CDC). CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). http://www.cdc.gov/HAI/settings/lab/vrsa_lab_search_containment.html. Accessed August 2, 2014.Google Scholar
3. Zhu, W, Clark, N, Patel, JB. pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro. Antimicrob Agents Chemother 2013;57:212219.Google Scholar
4. Zhu, W, Murray, PR, Huskins, WC, et al. Dissemination of an Enterococcus Inc18-like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:43144320.CrossRefGoogle ScholarPubMed
5. Tosh, PK, Agolory, S, Strong, BL, et al. Prevalence and risk factors associated with vancomycin-resistant Staphylococcus aureus precursor organism colonization among patients with chronic lower-extremity wounds in southeastern Michigan. Infect Control Hosp Epidemiol 2013;34:954960.Google Scholar
6. McDougal, LK, Fosheim, GE, Nicholson, A, et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother 2010;54:38043811.Google Scholar
7. Reyes, K, Malik, R, Moore, C, Donabedian, S, Perri, M, Johnson, L, Zervos, M. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2010;48:628630.Google Scholar
8. Melo-Cristino, J, Resina, C, Manuel, V, Lito, L, Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013;382(9888):205.Google Scholar
9. Rossi, F, Diaz, L, Wollam, A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014;370(16):15241531.Google Scholar